Zymeworks Inc. effective March 31, 2024 (the Separation Date), Zymeworks Inc. (the Company) removed Dr. Christopher Astle from the positions of Chief Financial Officer, including as the Company?s principal financial officer. Over the last two years in his position as Chief Financial Officer, Dr. Astle helped with the reset of the Company and to put the Company in a strong financial position.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
9.2 USD | +2.45% | +11.38% | -11.45% |
May. 02 | Transcript : Zymeworks Inc., Q1 2024 Earnings Call, May 02, 2024 | |
May. 02 | Zymeworks Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-11.45% | 656M | |
+8.96% | 105B | |
-1.43% | 104B | |
+5.07% | 22.94B | |
-12.15% | 22.34B | |
-6.59% | 19.25B | |
-39.98% | 17.08B | |
-10.04% | 16.96B | |
+38.61% | 12.63B | |
+313.59% | 8.49B |
- Stock Market
- Equities
- ZYME Stock
- News Zymeworks Inc.
- Zymeworks Inc. Removes Christopher Astle from the Positions of Chief Financial Officer